Stockscreener 앱 받기
18.70
3.37%
0.61
시간 외 거래:
18.41
-0.29
-1.55%
전일 마감가:
$18.09
열려 있는:
$18.08
하루 거래량:
738.10K
Relative Volume:
1.09
시가총액:
$531.09M
수익:
$320.35M
순이익/손실:
$-75.01M
주가수익비율:
-7.807
EPS:
-2.3953
순현금흐름:
$-113.17M
1주 성능:
+5.83%
1개월 성능:
+32.34%
6개월 성능:
-34.15%
1년 성능:
-9.53%
1일 변동 폭
$17.62
$18.96
1주일 범위
$17.40
$18.96
52주 변동 폭
$13.46
$31.04
Fulgent Genetics Inc Stock (FLGT) Company Profile
명칭
Fulgent Genetics Inc
전화
626-350-0537
주소
4399 SANTA ANITA AVE, EL MONTE
Compare FLGT vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FLGT
Fulgent Genetics Inc
|
18.70 | 513.77M | 320.35M | -75.01M | -113.17M | -2.3953 |
TMO
Thermo Fisher Scientific Inc
|
482.08 | 183.60B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
176.11 | 127.31B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
550.82 | 44.71B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
135.05 | 38.38B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
371.93 | 37.13B | 3.77B | 449.25M | 240.68M | 7.8556 |
Fulgent Genetics Inc Stock (FLGT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-05 | 업그레이드 | UBS | Neutral → Buy |
| 2023-12-07 | 개시 | UBS | Neutral |
| 2022-12-08 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-11-18 | 개시 | Raymond James | Outperform |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-02-04 | 재개 | Piper Sandler | Overweight |
| 2021-08-05 | 재개 | Credit Suisse | Underperform |
| 2021-01-08 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2020-11-24 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2020-08-20 | 개시 | Oppenheimer | Outperform |
| 2020-05-29 | 개시 | BTIG Research | Buy |
| 2019-11-05 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-03-01 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2017-11-07 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
모두보기
Fulgent Genetics Inc 주식(FLGT)의 최신 뉴스
Fulgent Presents Updated Phase 2 FID-007 + Cetuximab Data at ASCO Showing 61.9% ORR - TradingView
Fulgent Genetics (FLGT) Presents Promising Data on Head and Neck Cancer Treatment - GuruFocus
Strong FID-007 Phase 2 results for Fulgent Genetics (NASDAQ: FLGT) - Stock Titan
Fulgent Presents Updated FID-007 Data at ASCO 2026 - The Joplin Globe
Fulgent Genetics COO Jian Xie sells $21,137 in company stock - Investing.com
Fulgent Genetics (NASDAQ: FLGT) exec sells shares for tax withholding - Stock Titan
[Form 4] Fulgent Genetics, Inc. Insider Trading Activity - Stock Titan
Fulgent Genetics (FLGT) CSO sells 945 shares to cover tax obligations - Stock Titan
Ming Hsieh (FLGT) reports 32% Fulgent Genetics stake and major share pledges - Stock Titan
Fulgent Genetics (FLGT) CEO reports RSU tax withholding and large trust holdings - Stock Titan
Fulgent Genetics (FLGT) price target decreased by 28.85% to 18.87 - MSN
(FLGT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Law firm investigates Fulgent Genetics for possible securities law violations after revenue miss. - Pluang
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics - GlobeNewswire
Fulgent Genetics Presents Promising Phase 2 FID-007 & Cetuximab Data for Head and Neck Cancer at ASCO 2026 - Minichart
Fulgent reports interim data for cancer drug FID-007 trial By Investing.com - Investing.com Australia
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting - BioSpace
Fulgent reports interim data for cancer drug FID-007 trial - Investing.com
Fulgent Announces ASCO Rapid Oral Abstract Showing 60% ORR, 7.2‑mo mPFS for FID-007 plus Cetuximab - TradingView
Fulgent (NASDAQ: FLGT) reports 60% ORR in Phase 2 FID-007 cancer trial - Stock Titan
Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach - GlobeNewswire
Fulgent Genetics targets wider engagement at APG2026 San Diego exhibit fair - Traders Union
FLGT Stock Chart | FULGENT GENETICS INC (NASDAQ:FLGT) - ChartMill
Fulgent Genetics (FLGT) director receives stock units and 8,426-share option grant - Stock Titan
Fulgent Genetics (NASDAQ: FLGT) director receives 11,117 RSUs - Stock Titan
Fulgent Genetics (NASDAQ: FLGT) director awarded 11,117 restricted stock units - Stock Titan
Fulgent Genetics Shareholders Approve New 2026 Equity Plan - TipRanks
Fulgent Genetics (NASDAQ: FLGT) wins stockholder approval for 2026 equity plan - Stock Titan
ETFs Investing in Fulgent Genetics, Inc. Stocks - TradingView
Responsive Playbooks and the FLGT Inflection - Stock Traders Daily
Fulgent Genetics infertility test panels broaden to cover over 140 genes for females and 160 for males - Traders Union
TradingKey - TradingKey
LA500 2026: Ming Hsieh - Los Angeles Business Journal
Fulgent Genetics (NASDAQ:FLGT) Stock Passes Below Fifty Day Moving AverageHere's Why - MarketBeat
Fulgent Genetics (NASDAQ:FLGT) Stock Rating Lowered by Wall Street Zen - MarketBeat
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm - The Globe and Mail
Number of shareholders of Fulgent Genetics, Inc. – NASDAQ:FLGT - TradingView
Fulgent (FLGT) Q1 2026 Earnings Transcript - AOL.com
SEC EDGAR Submission 0000950170-25-062257 - SEC.gov
How many employees work at Fulgent Therapeutics? - Revelio Labs
Foundation Medicine links with Fulgent Genetics to offer new gene test - Fierce Biotech
Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics - BioSpace
PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics - Business Wire
Fulgent Genetics, Inc. (NASDAQ:FLGT) Q1 2026 Earnings Call Transcript - Insider Monkey
Fulgent Q1 2026 slides: revenue misses amid customer loss, therapy data shines - Investing.com Nigeria
Fulgent Genetics Reports Q1 2026 Results: $71M Revenue, Stock Buyback, Updated Guidance and Progress in Cancer Therapeutics - Minichart
Fulgent Genetics Inc (FLGT) Q1 2026 Earnings Call Highlights: Na - GuruFocus
Understanding the Setup: (FLGT) and Scalable Risk - Stock Traders Daily
Fulgent Genetics, Inc. Q1 2026 SEC 10-Q Filing: Financial Statements, Company Information, and Risk Disclosure - Minichart
Fulgent Genetics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Is Fulgent Genetics (FLGT) 38.5% Undervalued After Q1 2026? Reve - GuruFocus
Fulgent Genetics Inc (FLGT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.50%
1.15%
자본화:
|
볼륨(24시간):